Once-weekly albiglutide in the management of type 2 diabetes: patient considerations

Heather N Woodward 1
Sarah L Anderson 2

1 Centura St. Anthony’s Hospital, Lakewood, CO, USA; 2 Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

Abstract: This review describes the pharmacologic, pharmacokinetic, and pharmacodynamic properties of albiglutide, as well as its clinical efficacy and safety. Albiglutide is a novel, once-weekly, injectable glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. The European Commission recently granted marketing authorization for the drug in the European Union and on April 15, 2014, the US Food and Drug Administration approved albiglutide (Tanzeum™ [GlaxoSmithKline LLC, Wilmington, DE, USA]) to improve glycemic control in adults with type 2 diabetes. Albiglutide has been studied in Phase I, II, and III clinical trials. In the Phase III clinical trials, known as the Harmony series, weekly dosing of albiglutide demonstrated reductions in fasting plasma glucose, postprandial plasma glucose, and glycated hemoglobin, and was associated with weight loss. In all phases of the clinical trials, albiglutide administered once weekly showed a safety and tolerability profile similar to that of placebo, with mild gastrointestinal-related complaints and injection site erythema being the most commonly encountered adverse effects. Compared with pioglitazone and liraglutide, albiglutide has been shown to be clinically less effective. However, it offers the benefit of weight loss that pioglitazone does not, with fewer gastrointestinal side effects than liraglutide. As guidelines continue to advocate for patient-centered treatment strategies, once-weekly albiglutide will be an important addition to the growing armamentarium of treatment options for adults with type 2 diabetes needing target glycemic control.

Keywords: albiglutide, glucagon-like peptide 1 receptor agonist, drug therapy, type 2 diabetes mellitus

Introduction

Despite the advances in treatment available for type 2 diabetes mellitus, nearly 50% of patients with this condition fail to meet their glycemic target. 1 The barriers underlying this issue are several-fold, and include patient nonadherence to therapy and therapeutic inertia in a chronic disease state that frequently requires escalation of therapy. 1 Therapies that promote patient adherence and are synergistic with other antihyperglycemic agents are necessary to overcome these barriers.

Hyperglycemia is known to cause microvascular complications in patients with type 2 diabetes mellitus and trends have been observed between hyperglycemia and cardiovascular disease. 1,2 Despite these known risks, an exact treatment algorithm to manage hyperglycemia does not exist. Current guidelines support initiation of lifestyle modifications plus metformin as first-line monotherapy, and the treatment algorithm for adding or changing agents beyond that should be based on patient-specific factors. 2,3 One class of highly-effective agents that can be utilized for additional glycemic control are the glucagon-like peptide-1 (GLP-1) receptor agonists. As the native incretin hormone GLP-1, these agents activate the GLP-1 receptor to increase glucose-dependent insulin secretion, decrease glucose-dependent glucagon secretion, slow gastric
emptying, and increase satiety. GLP-1 receptor agonists decrease glycated hemoglobin (HbA1c), cause weight loss, and are low-risk for causing hypoglycemia.

Albiglutide (Tanzeum™) is a once-weekly GLP-1 receptor agonist developed by GlaxoSmithKline LLC (Wilmington, DE, USA) for the treatment of type 2 diabetes mellitus. The manufacturer received marketing authorization from the European Commission on March 26, 2014, and expects to launch albiglutide in several European countries by the end of 2014. On April 15, 2014, albiglutide was approved by the US Food and Drug Administration for improvement of glycemic control along with diet and exercise in adults with type 2 diabetes mellitus. Albiglutide is a novel compound comprised of a dipeptidyl peptidase-IV (DPP-IV)-resistant GLP-1 dimer fused to human albumin. The fusion to human albumin extends its half-life and makes once-weekly dosing possible. Less frequent dosing is a potential advantage over other GLP-1 receptor agonists that require once-daily or even twice-daily injections. An additional perceived benefit with albiglutide is that its large molecular size leads to less central nervous system penetration and thus fewer gastrointestinal adverse effects. This review discusses the pharmacology, efficacy, safety, and patient considerations regarding the use of albiglutide.

Pharmacology
Mechanism of action
In the human body, native GLP-1 released from enteroendocrine L-cells post-meal stimulates glucose-dependent insulin secretion and suppresses glucose-dependent glucagon secretion. Additionally, GLP-1 slows gastric emptying and subsequently reduces food intake, leading to modest weight loss. However, native GLP-1 is actively degraded by DPP-IV, which limits its therapeutic potential. Albiglutide is a GLP-1 receptor agonist created by the fusion of two 30 amino acid sequence repeats of human GLP-1 molecules to recombinant human albumin. An amino acid substitution (alanine at position 8 to glycine) confers resistance to DPP-IV, and the dual amino acid sequence fusion to human albumin enhances potency and extends the half-life to 5–8 days, making once-weekly dosing possible.

Pharmacokinetics
Several Phase I and Phase II studies have characterized the pharmacokinetic properties of albiglutide in healthy volunteers, Japanese patients with type 2 diabetes, and in non-Japanese patients with type 2 diabetes. Bush et al studied 39 healthy subjects (95% Hispanic/Latino) who received either placebo or escalating doses of albiglutide subcutaneously on day 1 (0.25 mg to 80 mg) and day 8 (1 mg to 104 mg). The median time taken to reach peak plasma concentration ranged from 2.3 to 4.0 days and the elimination half-life after day 8 ranged from 6.0 to 8.0 days for all doses.

Seino et al studied 40 Japanese patients with type 2 diabetes mellitus who received either albiglutide 15 mg weekly, 30 mg weekly, 50 mg biweekly, or 100 mg monthly over a 4-week period. The elimination half-life was slightly shorter than in the Phase I study by Bush et al at a median of 5.3 (range 4.6–5.9) days. The plasma clearance and volume of distribution of albiglutide were calculated to be 68.7 mL/hour and 12.6 L, respectively.

Studies by Rosenstock et al and Matthews et al evaluated the use of albiglutide in non-Japanese patients with type 2 diabetes mellitus. Matthews et al evaluated both the pharmacokinetics and pharmacodynamics of albiglutide in two separate studies, ie, a dose-escalation study and an injection site study. In the dose-escalation study, albiglutide was readily absorbed with a median lag time of 3.5 (0.00–18.5) hours in patients who received a 9 mg dose and 0.00 (0.00–8.5) hours in patients who received 16 mg and 32 mg doses. This means the larger doses of albiglutide (16 mg and 32 mg) had excellent bioavailability. The area under the curve for plasma drug concentration at week 1 and week 2 demonstrated slow drug accumulation, a trend similar to that seen in the study by Seino et al. The time taken to reach peak plasma concentration ranged from 2.99 to 5.0 days, and the elimination half-life was 5.73–6.8 days.

The injection site study evaluated the relative bioavailability of a single dose (16 mg or 64 mg) of albiglutide in the arm, leg, or abdomen in 46 patients. There were no significant effects of injection site on the pharmacokinetic parameters. A dose-dependent increase in elimination half-life and plasma area under the curve for the drug was observed.

Rosenstock et al evaluated a larger cohort of 356 patients with type 2 diabetes mellitus who received placebo or albiglutide weekly (4 mg, 15 mg, or 30 mg), biweekly (15 mg, 30 mg, or 50 mg) or monthly (50 mg or 100 mg). Albiglutide reached steady state within 4–5 weeks and had an elimination half-life of approximately 5 days.

These five trials established that albiglutide is a drug amenable to once-weekly dosing by demonstrating an elimination half-life of 5–8 days with peak plasma levels achieved in 2.3–5 days.
Pharmacodynamics
The pharmacodynamic parameters that have been evaluated for albiglutide include its effects on glucose, insulin, C-peptide, glucagon, fasting plasma glucose, postprandial plasma glucose, free fatty acids, and fructosamine. Healthy subjects who received increasing doses of albiglutide showed a trend of dose-dependent reduction in glucose and fructosamine levels. In these healthy subjects, there were no dose-dependent effects seen for glucagon, insulin, or C-peptide concentrations. In a study of Japanese patients with type 2 diabetes mellitus who were randomized to receive albiglutide 15 mg or 30 mg once weekly, 50 mg every 2 weeks, or 100 mg monthly, the mean weighted glucose (area under the curve) after 4 weeks was significantly decreased in all patients except for those who received the 100 mg dose (all P≤0.002 except for the 100 mg dose, P=0.065). The placebo-adjusted mean plasma glucose was also significantly decreased in all groups except for the 100 mg group (all P≤0.001 except for the 100 mg dose, P=0.613). These results were reproduced 2 weeks after the treatment period ended. Greater fluctuations in fasting plasma glucose were seen with biweekly and monthly doses, whereas once-weekly doses of albiglutide produced more consistent results. In the second study, significant reductions in placebo-adjusted least square means for the glucose (mg/dL) area under the curve were seen in the 9 mg, 16 mg, and 32 mg albiglutide groups at days 2 and 9. Postprandial glucose reductions were similar. Phases II clinical trials
Rosenstock et al investigated the safety, efficacy, and tolerability of escalating doses of albiglutide in patients with uncontrolled type 2 diabetes mellitus (baseline HbA1c 7.9%–8.2%, average duration of type 2 diabetes mellitus 3.9–6.4 years, see Table 1). Exenatide was included as an open-label clinical reference. There was a consistent trend of weight reduction observed across all doses of albiglutide (ranging from −1.1 kg to −1.7 kg) but was less than in patients who received exenatide (−2.4 kg). The most frequently reported adverse effects were nausea (12%–54%), vomiting (8.6%–41%), diarrhea (5.7%–22%), and headache (11.4%–23.5%). Gastrointestinal adverse effects were largely dose-dependent but declined over the course of the study. Injection site reactions were more common with albiglutide (28.6%) than with placebo (2.9%) and exenatide (2.9%), but were mainly mild and unrelated to dose or frequency of administration. No serious episodes of hypoglycemia occurred. Anti-albiglutide antibodies were detected in eight patients; however, three of these patients had positive titers at baseline, suggesting that immunogenicity may be overestimated. Overall, albiglutide improved glucose control in a dose-dependent manner, with a higher frequency of gastrointestinal adverse effects in the monthly dosing groups. Seino et al compared the safety, pharmacokinetics, and pharmacodynamics of escalating doses of albiglutide in Japanese patients with uncontrolled type 2 diabetes mellitus. The patients were primarily male (87.5%) and had a mean body mass index of 24.53 kg/m² (Table 1). Baseline characteristics were similar for all but the 30 mg weekly group, which had a lower mean body weight at baseline. Forty patients were randomized to receive albiglutide 15 mg or 30 mg once weekly, 50 mg biweekly, 100 mg monthly, or placebo over a 4-week period. Weight changes with albiglutide ranged from −0.8 kg to +0.2 kg, with the 50 mg group experiencing the largest degree of weight loss. However, the placebo group also lost weight (−0.3 kg). Adverse effects were most common in the 100 mg albiglutide group; flatulence (37.5%, n=3), vomiting (37.5%, n=3), and nausea (25%, n=2) were reported most frequently in this group. Nausea, abdominal pain, diarrhea, and hypoglycemia were each reported once in the 15 mg cohort, and one patient in the placebo group experienced flatulence. There was one report of injection site erythema in the 30 mg group. The difference in injection site reactions between this study and the study by Rosenstock et al cannot readily be attributed to sample size and is therefore unknown. Anti-albiglutide antibodies were not detected in any treatment group.
A more recently published Phase Iib study by Seino et al compared the safety and efficacy of albiglutide 15 mg weekly, 30 mg weekly, and 30 mg biweekly versus placebo in 215 Japanese patients with type 2 diabetes mellitus (Table 1). The primary end point was change in HbA$_1c$ at week 16. All doses of albiglutide resulted in a statistically significant decrease in HbA$_1c$ when compared with placebo; the largest decrease was observed in the 30 mg weekly group (−1.55%, $P<0.001$). In the 30 mg weekly group, 63.0% of patients achieved an HbA$_1c$ <7.4% by week 16 compared with 6.0% in the placebo group. The mean change in body weight was <1 kg for all treatment groups and was not statistically significant. The most common adverse effects in the treatment groups were nasopharyngitis, injection site reactions, and diarrhea, which were all comparable with placebo. Other gastrointestinal adverse effects were comparable with placebo and occurred at less frequent rates than in the study by Rosenstock et al.$^{16}$

Matthews et al investigated the pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide in patients with type 2 diabetes mellitus taking metformin and sulfonylureas, either alone or in combination (Table 1). Two separate studies were performed, ie, a dose-escalation and an injection site study. After a 2-week washout of prior oral antihyperglycemic medications, 54 patients were randomized to receive placebo or albiglutide 9 mg, 16 mg, or 32 mg on days 1 and 8. Fasting and postprandial plasma glucose reductions at all time points were similar between the albiglutide groups. In the injection site study, 46 patients were randomized to receive a single dose of 16 mg or 64 mg of albiglutide injected into the arm, leg, or abdomen. The most common adverse events over the 9-day treatment course were headache and nausea, rates of which were comparable between the placebo and treatment groups and not dose-dependent. No hypoglycemic episodes or electrocardiographic abnormalities were reported in the albiglutide groups.$^{15}$

### Phase III clinical trials

Based on the efficacy, safety, and tolerability of albiglutide doses in the Phase I and II trials, albiglutide 30 mg and 50 mg once weekly were evaluated in eight Phase III trials, collectively known as the Harmony program. This program investigated the efficacy, tolerability, and safety of albiglutide as monotherapy or as add-on therapy in approximately 5,000 patients with type 2 diabetes mellitus.
Harmony 1 evaluated the safety and efficacy of albiglutide as add-on therapy in patients inadequately controlled on pioglitazone with or without metformin (Table 2). Patients were randomized to receive either albiglutide 30 mg subcutaneously once weekly or placebo in addition to their baseline regimen of pioglitazone with or without metformin. Patients reaching predefined HbA\textsubscript{lc} thresholds were started on hyperglycemic rescue therapy but remained on blinded treatment during the trial. At week 52, both HbA\textsubscript{lc} and fasting plasma glucose were significantly decreased relative to baseline in those receiving albiglutide compared with placebo (both \(P<0.001\)). Forty-four percent of patients receiving albiglutide achieved an HbA\textsubscript{lc}<7% compared with only 15% of those receiving placebo.\textsuperscript{18}

Hyperglycemic rescue was used in 40.9% of patients in the placebo group but in only 22.7% of the albiglutide group (with insulin as rescue therapy in 21.2% and 10%, respectively). Both groups experienced a similar change in weight from baseline. Treatment was discontinued due to adverse events in 3.2% of the albiglutide group and in 6.3% in the placebo group. Rates of nausea and vomiting were similar between albiglutide (10.7%, 4.0%) and placebo (11.3%, 4.0%) while rates of diarrhea (11.3% versus 8.6%) and injection site reactions (11.3% versus 7.9%) were slightly higher in those receiving albiglutide. The incidence of documented symptomatic hypoglycemia (blood glucose \(\leq70\) mg/dL) was 3% for albiglutide (versus 1% for placebo). The rate of severe hypoglycemia in the albiglutide arm was 1%.\textsuperscript{18} This study demonstrated the clinical efficacy and tolerability of albiglutide as add-on therapy for patients who are uncontrolled on pioglitazone with or without metformin.

Harmony 2 examined the safety and efficacy of albiglutide monotherapy versus placebo in drug-naïve patients with type 2 diabetes mellitus (Table 2). Patients were randomized to receive either albiglutide 30 mg or 50 mg or placebo subcutaneously once weekly. Those in the albiglutide 50 mg group were started on 30 mg and increased to 50 mg at week 12. Patients were allowed to continue in the study if hyperglycemic rescue was required. At week 52, HbA\textsubscript{lc} and fasting plasma glucose levels were significantly decreased relative to baseline for both albiglutide 30 mg and 50 mg compared with placebo. A target HbA\textsubscript{lc} of <7% was achieved in 49.0% of the albiglutide 30 mg group, 40.9% of the albiglutide 50 mg group, and in none of the patients in the placebo group. Hyperglycemic rescue was required in 50% of those in the placebo group, 20% in the albiglutide 30 mg group, and 16% in the albiglutide 50 mg group. Metformin was preferentially recommended for hyperglycemic rescue. A similar decrease in weight was reported in all groups. Treatment was discontinued due to adverse events in 2% of the placebo group, 5% of the 30 mg group, and 13% of the 50 mg group. The most common adverse effects were gastrointestinal and similar between groups. Injection site reactions were higher in the two albiglutide arms (10% placebo, 18% albiglutide 30 mg, 22% albiglutide 50 mg) but most were mild in nature. There were no reports of severe hypoglycemia, acute pancreatitis, or thyroid cancer in the albiglutide groups.\textsuperscript{19}

Harmony 2 demonstrated the clinical efficacy of the 30 mg and 50 mg doses of albiglutide, with similar rates of gastrointestinal adverse events occurring in all groups. Albiglutide was also shown to be a safe option for monotherapy in drug-naïve patients with type 2 diabetes mellitus.

Harmony 3 compared the efficacy and safety of albiglutide with that of sitagliptin, glimepiride, and placebo when added to baseline metformin therapy (Table 2). Two run-in treatments were started in all patients, ie, metformin (up titrated to a maximum tolerated dosage over 2 weeks) and a diet and exercise regimen (1 week prior to randomization). Patients were then randomized to receive either albiglutide 30 mg weekly, sitagliptin 100 mg orally once daily, glimepiride 2 mg to 4 mg orally once daily, or a weekly placebo injection. Patients reaching predefined hyperglycemic thresholds qualified for blinded dose titration (albiglutide 30 mg to 50 mg and glimepiride 2 mg to 4 mg). At week 104, the mean HbA\textsubscript{lc} increased in the placebo group and decreased in all treatment groups compared with baseline. However, the albiglutide group had a significantly greater reduction in HbA\textsubscript{lc} compared with the sitagliptin and glimepiride groups. The albiglutide group also had a significantly greater reduction in fasting plasma glucose when compared with placebo, sitagliptin, and glimepiride. Hyperglycemic rescue with insulin therapy was initiated at an HbA\textsubscript{lc} of 8.5% and occurred in the albiglutide, glimepiride, sitagliptin, and placebo groups in 26%, 33%, 36%, and 59% of patients, respectively. Weight loss was similar in the placebo, albiglutide, and sitagliptin groups but increased in the glimepiride group. Treatment was discontinued due to adverse events at similar rates across the treatment arms. Common adverse events attributed to placebo, sitagliptin, glimepiride, and albiglutide included nausea (11%, 7%, 6%, and 10%, respectively), vomiting (1%, 4%, 4%, and 6%), diarrhea (11%, 9%, 9%, and 13%), and upper respiratory tract infection (10%, 9%, 9%, and 16%). However, the prevalence of nausea or vomiting in albiglutide-treated patients declined by week 8 of treatment to a rate similar to that in the sitagliptin and placebo groups, but less than that in the
### Table 2 Phase III clinical trials of albiglutide

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Duration</th>
<th>Treatment</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reusch et al(^6)</td>
<td>Patients with T2DM inadequately controlled on pioglitazone ± metformin</td>
<td>52 weeks</td>
<td>Placebo + pioglitazone ± metformin</td>
<td>Change in HbA(_1c) from baseline</td>
</tr>
<tr>
<td>Harmony 1</td>
<td>R, DB, PC, PG</td>
<td>52 weeks</td>
<td>Albiglutide 30 mg once weekly + pioglitazone ± metformin</td>
<td>Treatment difference, albiglutide 30 mg versus placebo: −0.75% (95% CI, −0.95, −0.56)</td>
</tr>
<tr>
<td>Reinhardt et al(^5)</td>
<td>n=296 Drug-naïve patients with T2DM inadequately controlled with diet and exercise</td>
<td>52 weeks</td>
<td>Placebo</td>
<td>Change in FPG from baseline</td>
</tr>
<tr>
<td>Harmony 2</td>
<td>R, DB, PC, PG</td>
<td>52 weeks</td>
<td>Albiglutide 30 mg once weekly</td>
<td>Treatment difference, albiglutide 30 mg versus placebo: −0.84% (95% CI, −1.11, −0.58)</td>
</tr>
<tr>
<td>Ahrén et al(^7)</td>
<td>n=999 Patients with T2DM inadequately controlled on metformin</td>
<td>104 weeks</td>
<td>Placebo + metformin</td>
<td>Change in body weight from baseline</td>
</tr>
<tr>
<td>Harmony 3</td>
<td>R, DB, AC, PG</td>
<td></td>
<td>Albiglutide 30 mg once weekly + metformin</td>
<td>Treatment difference, albiglutide 50 mg versus placebo: −1.04% (95% CI, −1.31, −0.77)</td>
</tr>
<tr>
<td>Pratley et al(^8)</td>
<td>n=779 Patients with T2DM inadequately controlled on metformin ± sulfonylurea</td>
<td>52 weeks</td>
<td>Insulin glargine 10 units (option to uptitrate) once daily</td>
<td>Change in FPG from baseline</td>
</tr>
<tr>
<td>Harmony 4</td>
<td>R, OL, PG</td>
<td></td>
<td>Albiglutide 30 mg (option to uptitrate to 50 mg) once weekly</td>
<td>Treatment difference, albiglutide 30 mg versus placebo: −0.2 kg (95% CI, −1.2, 0.8)</td>
</tr>
</tbody>
</table>

- **FPG**: Fasting Plasma Glucose
- **HbA\(_1c\)**: Glycated Hemoglobin
- **CGM**: Continuous Glucose Monitoring
- **BMI**: Body Mass Index
- **NS**: Non Significant
- **CI**: Confidence Interval
- **DB**: Double-Blind
- **OL**: Open-Label
- **AC**: Active Control
- **PC**: Placebo-Controlled
- **PG**: Parallel-Group
- **R**: Randomized
- **OL**: Open-Label
<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Duration</th>
<th>Treatment</th>
<th>Change in HbA(_1c) from baseline</th>
<th>Change in weight from baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stewart et al(^{17}) Harmony 5&lt;br&gt;R, DB, MC</td>
<td>Patients with T2DM inadequately controlled on metformin (≥1,500 mg/day) + glimepiride 4 mg/day</td>
<td>52 weeks</td>
<td>Placebo&lt;br&gt;Albiglutide 30 mg (option to uptitrate to 50 mg) once weekly&lt;br&gt;Pioglitazone 30 mg (option to uptitrate to 45 mg) once daily&lt;br&gt;All patients remained on metformin and glipizide therapy</td>
<td>Treatment difference, albiglutide versus placebo: −0.87% (95% CI, −1.07, −0.68)</td>
<td>Treatment difference, albiglutide versus glimepiride: −1.11% (95% CI, −1.31, −0.91)</td>
</tr>
<tr>
<td>Fonesca et al(^{11}) Rosenstock et al(^{14}) Harmony 6&lt;br&gt;OL, AC, PG</td>
<td>Patients with T2DM inadequately controlled on insulin glargine and oral agents</td>
<td>26 weeks, 52 weeks</td>
<td>Albiglutide 30 mg once weekly + titrated insulin glargine&lt;br&gt;Prandial insulin lispro + titrated insulin glargine&lt;br&gt;Both groups continued on oral agents with the exception of sulfonylureas not allowed</td>
<td>Change in HbA(_1c) from baseline at week 26: 0.16% (95% CI, −0.32, 0%)&lt;br&gt;95% CI pre-specified non-inferiority margin was met&lt;br&gt;Change in weight from baseline at week 26: −4.9 kg (95% CI, −7.0, −2.8)</td>
<td>Treatment difference, albiglutide versus insulin lispro: −0.17% (95% CI, −0.35, 0.02), prespecified noninferiority was not met</td>
</tr>
<tr>
<td>Pratley et al(^{12}) Harmony 7&lt;br&gt;R, DB, OL, PG</td>
<td>Patients with T2DM inadequately controlled on metformin, thiazolidinedione, sulfonylurea, or any combination of these</td>
<td>32 weeks</td>
<td>Albiglutide titrated to 50 mg once weekly&lt;br&gt;Liraglutide titrated to 1.8 mg once daily</td>
<td>Treatment difference, albiglutide versus liraglutide: −0.21% (95% CI, 0.08, 0.34), prespecified noninferiority was not met&lt;br&gt;Change in weight from baseline: −3.9 mg/dL versus liraglutide: −2.0 mg/dL (P=0.01)</td>
<td>Treatment difference, albiglutide versus liraglutide: −0.21% (95% CI, 0.08, 0.34), prespecified noninferiority was not met&lt;br&gt;Change in weight from baseline: −2.0 mg/dL versus liraglutide: −1.0 mg/dL (P=0.01)</td>
</tr>
<tr>
<td>Leiter et al(^{20}) Harmony 8&lt;br&gt;R, DB, PG, MC</td>
<td>Patients with T2DM and renal insufficiency (eGFR 15 and &lt; 90 mL/min/1.73 m(^2)) inadequately controlled on metformin, thiazolidinedione, sulfonylurea, lifestyle changes or any combination of these</td>
<td>26 weeks</td>
<td>Albiglutide 30 mg (titrated to 50 mg if needed) once weekly&lt;br&gt;Sitagliptin adjusted for renal function</td>
<td>Change in HbA(_1c) from baseline: −0.8 kg versus sitagliptin: −0.2 kg (P=0.0281)</td>
<td>Treatment difference for any degree of renal function, albiglutide versus sitagliptin: −0.32% (95% CI, −0.49, −0.15)</td>
</tr>
</tbody>
</table>

**Abbreviations:** HbA\(_1c\), glycated hemoglobin; AC, active control; CI, confidence interval; DB, double-blind; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; MC, multicenter; NS, non significant; OL, open-label; PC, placebo-controlled; PG, parallel-group; R, randomized; T2DM, type 2 diabetes mellitus.
glimepiride group. Injection site reactions in the albiglutide group were mostly mild or moderate in nature (17%). The incidence of documented symptomatic hypoglycemic (blood glucose ≤70 mg/dL) events (prior to addition of hyperglycemia rescue medication) was 4% with placebo, 2% with sitagliptin, 18% with glimepiride, and 3% with albiglutide. Two patients on albiglutide had probable pancreatitis that was possibly related to their treatment, and one patient developed thyroid cancer. Results from Harmony 3 demonstrated that albiglutide lowered HbA1c to a greater degree than glimepiride and sitagliptin, with gastrointestinal adverse effects attenuating by around week 8 of treatment. This was also the first trial in the Harmony series to raise concerns about the debated class effect of pancreatitis and thyroid cancer.

Harmony 4 compared the safety and efficacy of albiglutide 30 mg once weekly with that of insulin glargine when added to metformin and/or a sulfonylurea in patients with type 2 diabetes mellitus (Table 2). Patients were randomized to receive albiglutide 30 mg once weekly (titrated to 50 mg weekly if needed) or insulin glargine daily (titrated individually if needed) to a target HbA1c ≤7.0% and a fasting plasma glucose ≤100 mg/dL. Eighty-two percent of patients continued baseline metformin and a sulfonylurea. By week 47, 39.1% of patients treated with albiglutide had been uptitrated to 50 mg. Insulin glargine was started at a median dose of 10 (range 2–40) units and increased to a median of 30 (range 3–152) units by week 52. At week 52, a goal HbA1c of <7% was reached at similar rates in the albiglutide (32%) and insulin glargine (33%) groups. Reduction from baseline HbA1c was also similar between albiglutide (~0.67%) and insulin glargine (~0.79%), with a treatment difference that met the prespecified criterion for declaring noninferiority of albiglutide to insulin glargine. There was a significant difference in fasting plasma glucose in favor of insulin glargine compared with albiglutide. Those in the albiglutide group lost weight, while those on insulin glargine gained weight.

Common adverse events that occurred at similar rates in the albiglutide and insulin glargine groups were vomiting (3.8% versus 3.7%) and upper respiratory tract infection (9% versus 10%). Nausea and diarrhea were more prevalent in the albiglutide group (9.9% and 7.5%, respectively) when compared with the insulin glargine group (4.1% and 3.7%). Injection site reactions were also more common in the albiglutide group than in the glargine group (13.9% versus 8.7%, respectively). Documented symptomatic hypoglycemia (blood glucose ≤70 mg/dL) occurred less often in the albiglutide group (21%) than in the insulin glargine group (29%), and was associated with concurrent sulfonylurea use. Severe hypoglycemic events were similar between the groups (both 0.4%). Two patients in the albiglutide group and one patient in the insulin glargine group developed pancreatitis during the study. An independent blinded pancreatitis adjudication committee identified one patient in the albiglutide group as having probable pancreatitis that was at least possibly related to the study drug. No patients developed thyroid cancer. Results from Harmony 4 demonstrated that there was no statistically significant difference between albiglutide and insulin glargine with regard to reduction in HbA1c after 52 weeks of therapy (P=0.15). Nausea, diarrhea, and injection site reactions occurred more frequently in the albiglutide group, while vomiting and upper respiratory tract infection occurred at similar rates between the groups. Most adverse events were mild to moderate in intensity.

Harmony 5 compared the efficacy and safety of albiglutide weekly with that of pioglitazone when added to a baseline regimen of metformin and glimepiride (Table 2). Patients were randomized to albiglutide 30 mg once weekly, pioglitazone 30 mg once daily, or placebo. Baseline metformin and glimepiride regimens were continued. Albiglutide was increased from 30 mg to 50 mg once weekly and pioglitazone from 30 mg to 45 mg daily at weeks 4 and 12 if fasting plasma glucose was >250 mg/dL and thereafter if HbA1c was >7%. Patients were allowed to continue if hyperglycemic rescue was required. Upitation occurred in 70.1% of patients in the albiglutide group in 54.9% of patients in the pioglitazone group. At week 52, the mean reduction in HbA1c in the albiglutide group was statistically significant versus the placebo group, but noninferiority was not achieved versus pioglitazone. The percentage of patients achieving an HbA1c goal <7% was slightly higher for pioglitazone (35%) than for albiglutide (30%), but both were higher than placebo (9%). The pioglitazone group also had a significantly greater decrease in fasting plasma glucose versus the albiglutide group. The albiglutide and placebo groups experienced a mean weight loss, while the pioglitazone group experienced weight gain. More patients in the pioglitazone and placebo groups withdrew from the study due to adverse events (6.9% and 5.2%, respectively) when compared with the albiglutide group (4.4%). Gastrointestinal adverse events were experienced less frequently in the placebo and pioglitazone groups than in the albiglutide group, and comprised nausea (3.5%, 4.3%, and 9.6%, respectively), diarrhea (2.6%, 5.4%, and 8.9%), and vomiting (0.9%, 1.8%, and 2.6%). Injection site reactions were also more common in the albiglutide group (12.9%) than in the placebo (3.5%) and pioglitazone (3.2%) groups, but the majority of reactions were mild. The rate of severe hypoglycemia in the albiglutide group was 0.4% and higher.
in the pioglitazone group at 1.1%. Four patients in total (three in the albiglutide group and one in the placebo group) were evaluated for pancreatitis. Two patients in the albiglutide arm of the study were identified as having probable pancreatitis that was possibly related to the study drug. This study demonstrated that, when added to baseline metformin and glimepiride, albiglutide significantly decreased HbA1c at week 52 relative to placebo but did not meet the criteria for noninferiority when compared with pioglitazone. Gastrointestinal and injection site adverse events were more common with albiglutide but were generally mild in nature.

Harmony 6 compared once-weekly albiglutide versus prandial insulin lispro, both combined with titrated insulin glargine (Table 2). After an initial run-in period with insulin glargine, patients were randomized to receive albiglutide 30 mg once weekly or meal-time insulin lispro and continued on home metformin and/or thiazolidinedione therapy. Both groups also received insulin glargine titrated to target a fasting plasma glucose of 80–130 mg/dL. Insulin lispro was adjusted as per the prespecified algorithm based on blood glucose monitoring, and albiglutide could be uptitrated to 50 mg once weekly based on progressively lower HbA1c targets. Hyperglycemia rescue was permitted in both treatment arms based on HbA1c thresholds. At 26 weeks, both groups experienced a reduction in HbA1c from baseline (albiglutide −0.82%±0.06% and insulin lispro −0.66%±0.06%), with a treatment difference that met prespecified noninferiority, with a trend toward superiority (P=0.053). At 52 weeks, both groups experienced a further decrease in HbA1c, but at this time point, albiglutide did not meet noninferiority versus insulin lispro (−1.01%±0.07% and −0.84%±0.06%, respectively; P=0.086). At week 26, there were similar decreases in fasting plasma glucose with albiglutide and insulin lispro (−18 mg/dL and −13 mg/dL, respectively; P=0.236), but these were significantly lower by week 52 with albiglutide versus lispro (−27 mg/dL and −16 mg/dL, respectively; P=0.028). At week 52, the target HbA1c level of <7.0% was reached in 45% of those receiving albiglutide and 30% of those receiving insulin lispro (P=0.231 for treatment difference). The average dose of glargine was similar between the albiglutide and insulin lispro groups and a similar percentage of patients in each group required hyperglycemic rescue (43.5% and 38.8%, respectively, at week 52, P=0.326).

Throughout the study, patients on albiglutide lost weight while those on insulin lispro gained weight (−0.96 kg and +1.66 kg, respectively; P<0.001). Interestingly, 158 patients in the albiglutide arm and 137 patients in the insulin lispro arm failed to complete the study; the reason for this is unknown.

Adverse events were more common in the albiglutide group than in the insulin lispro group, with nausea (13% versus 2%), diarrhea (14% versus 6%), and injection site reactions (10% versus 5%) being the most common. Hypoglycemia (blood glucose ≤70 mg/dL) was reported in 23% of those receiving albiglutide compared with 39% of those receiving insulin lispro. No severe hypoglycemic events were reported for albiglutide (1% for lispro). Harmony 6 demonstrated that albiglutide produced clinically relevant reductions in HbA1c that were comparable with those achieved on insulin lispro, with less hypoglycemia and slightly higher rates of gastrointestinal adverse events.

Harmony 7 was a noninferiority trial that compared albiglutide 50 mg once weekly with liraglutide 1.8 mg once daily in patients with type 2 diabetes mellitus (Table 2). After a 4 week run-in period, patients were randomized to receive either albiglutide 30 mg once weekly (titrated up to 50 mg once weekly at week 6), or liraglutide 0.6 mg daily (titrated to 1.8 mg daily at week 3). Patients who had predefined hyperglycemia could begin rescue treatment after week 2, with insulin as the preferred add-on agent. At week 32, albiglutide demonstrated less glycemic efficacy when compared with liraglutide. Baseline HbA1c changed by −0.78%±0.99% with albiglutide and −0.99%±1.02% with liraglutide, but the treatment difference did not meet the noninferiority criterion (P=0.085).

The treatment goals of HbA1c <7% and ≤6.5% were met in a significantly greater percentage of those receiving liraglutide versus those receiving albiglutide (52% and 28% versus 42% and 20%; P=0.002 and P=0.001, respectively). Changes in fasting plasma glucose from baseline mirrored changes in HbA1c and were significantly lower in the liraglutide group versus the albiglutide group. By week 32, hyperglycemic rescue occurred in a higher percentage of those in the albiglutide group (15%) versus the liraglutide group (8%), and the time to hyperglycemic rescue was longer for the liraglutide group (P=0.005). Weight significantly decreased from baseline in both groups but the decrease was significantly greater with liraglutide. Gastrointestinal adverse events were common in both groups, but occurred more often in the liraglutide group than in the albiglutide group (49.0% versus 35.9%; P=0.001). Study withdrawal due to gastrointestinal adverse events was also more common in the liraglutide group (6.4%) than in the albiglutide group (2.5%). The most common adverse events were diarrhea, upper respiratory tract infection, nausea, vomiting, and injection site reactions. Diarrhea occurred at similar rates between the groups (albiglutide 14.9%, liraglutide 13.5%; P=0.575) as did upper respiratory tract infection (albiglutide
10.4%, liraglutide 11%; P=0.771). However, nausea was significantly more common with liraglutide (29.2%) than with albiglutide (9.9%; P<0.001), as was vomiting (albiglutide 5% versus liraglutide 9.3%; P=0.015). Injection site reactions were significantly more common with albiglutide than with liraglutide (6.9% versus 1.2%; P<0.001). Symptomatic hypoglycemia occurred in 16.3% of those receiving albiglutide and in 20.8% of those receiving liraglutide. Most of these hypoglycemic events occurred with concomitant sulfonylurea use. There were no documented cases of severe hypoglycemia. One person in the albiglutide group and two in the liraglutide group were determined to have probable or definite pancreatitis that was possibly related to treatment. This head-to-head trial of GLP-1 receptor agonists demonstrated that albiglutide was less clinically efficacious than liraglutide but was associated with significantly less nausea and vomiting. Discontinuation of therapy due to gastrointestinal adverse events was more common in the liraglutide group, which may have implications for patient adherence. Hypoglycemic episodes were more common in the liraglutide group than in the albiglutide group, and were most common with concurrent sulfonylureas. This finding, along with the higher rate of hypoglycemia in the sulfonylurea arm of the Harmony 3 trial, may limit the concurrent use of sulfonylureas with GLP-1 receptor agonists.20,25

Harmony 8 compared albiglutide 30 mg once weekly with sitagliptin daily in patients with type 2 diabetes mellitus and any degree of renal impairment (mild, moderate, severe; estimated glomerular filtration rate ≥15 and <90 mL/min/1.73 m², see Table 2). Patients were randomized to receive albiglutide (30 mg weekly, titrated to 50 mg weekly based on glycemic response) plus placebo or sitagliptin (25 mg to 100 mg, depending on degree of renal impairment) plus placebo. The degree of renal impairment was similar between the groups. At 26 weeks, patients on albiglutide showed a clinically and statistically significant reduction in HbA₁c from baseline for any degree of renal impairment (−0.83%) compared with sitagliptin (−0.52%), with a treatment difference achieving not only noninferiority but also superiority (P=0.003) in favor of albiglutide. A goal HbA₁c of <7% was achieved by 42.6% in the albiglutide group and by 30.5% in the sitagliptin group. Fasting plasma glucose was also significantly decreased in the albiglutide group versus the sitagliptin group.26

Weight loss was significantly greater in the albiglutide group versus sitagliptin. The most common adverse events were nausea (albiglutide 4.8%, sitagliptin 3.3%), diarrhea (albiglutide 8.8%, sitagliptin 6.1%), and vomiting (albiglutide 1.6%, sitagliptin 1.2%). Documented hypoglycemia (blood glucose <70 mg/dL) prior to rescue medications occurred in 10.4% of the albiglutide group (0% severe) and in 5.7% of the sitagliptin group (0.8% severe). Injection site reactions occurred in 6.8% of the albiglutide group and in 2.8% of the sitagliptin group.26 Harmony 8 is the only trial in the Harmony program to explore the efficacy and safety of albiglutide in those with any degree of renal impairment. Albiglutide demonstrated superior clinical efficacy compared with sitagliptin, with similar to slightly higher rates of gastrointestinal adverse events and less hypoglycemia. This is an important finding given that many patients with type 2 diabetes mellitus have concomitant renal impairment.

Summary of Phase III trials

The Harmony program assessed the efficacy, safety, and tolerability of once-weekly albiglutide in patients with type 2 diabetes mellitus who were previously uncontrolled with various combinations of oral antihyperglycemic agents, insulin, and/or diet and exercise. Baseline patients characteristics were similar in each trial. Baseline HbA₁c ranged from 8.1% to 8.5%, patients had a mean duration of type 2 diabetes mellitus of 4–9 years, were aged 53–63 years, and approximately 40%–52% were female.18,26

Albiglutide demonstrated greater efficacy in lowering HbA₁c as add-on therapy to metformin when compared with glimepiride and sitagliptin. Significant HbA₁c and fasting plasma glucose reductions were also achieved when albiglutide was added to various combinations of pioglitazone, glimepiride, and metformin. Importantly, albiglutide was found to be noninferior to insulin glargine and at week 26 of 52 when compared with mealtime insulin lispro. Superiority of albiglutide over sitagliptin was achieved in a noninferiority trial in patients with renal impairment. However, albiglutide failed to achieve noninferiority when compared head-to-head with pioglitazone and liraglutide. Weight loss was moderate across the studies, and the class effect of gastrointestinal side effects was evident, although less common than with liraglutide.18–26 These findings may direct the use of albiglutide to those who need an additional reduction in HbA₁c and desire moderate weight loss, but are unable to tolerate other GLP-1 receptor agonists. The data from the Harmony series should confirm for practitioners and patients that this is an effective therapeutic option for type 2 diabetes mellitus.

Dosage and administration

GlaxoSmithKline recently approved once-weekly subcutaneous albiglutide 30 mg and 50 mg in the USA.4 Although it is an injectable agent, its once-weekly administration
may be appealing to patients and may increase adherence over a product that is dosed once or multiple times per day.\textsuperscript{11}

Precautions and contraindications

The safety of albiglutide in patients with renal impairment (estimated glomerular filtration rate \( \geq 15 \) and \(< 90 \text{ mL/min/1.73 m}^2 \)) was studied in the Harmony 8 trial. Albiglutide was found to be both efficacious and safe in this population, with diarrhea and nausea being the most common side effects.\textsuperscript{26} More data are necessary to confirm these findings, but these initial data demonstrate albiglutide to be an effective therapy in patients with renal impairment.

As a class, GLP-1 receptor agonists have been implicated in case and post-marketing reporting as being associated with an increased risk of pancreatitis, pancreatic cancer, and thyroid cancer.\textsuperscript{27} The reported incidence of pancreatitis in patients using the GLP-1 receptor agonist exenatide ranges from 0.33 to 5.7 cases per 1,000 patient years.\textsuperscript{28,29} The rates of necrotizing or hemorrhagic pancreatitis in exenatide users is much smaller at less than one in 10,000, which is similar to the rates in all patients with diabetes.\textsuperscript{30} GLP-1 receptor agonists have been associated with an increased risk of pancreatic cancer, but both the US Food and Drug Administration and the European Medicines Agency have concluded that there is insufficient evidence to suggest a causal relationship.\textsuperscript{31,32} Animal studies of both liraglutide and exenatide once weekly demonstrated an association with use of each agent and the development of thyroid C-cell tumors; however, this association has not been found in human data.\textsuperscript{33}

Based on these concerns regarding pancreatitis, pancreatic cancer, and thyroid cancer, it is recommended to avoid the use of exenatide in patients with a history of pancreatitis and to avoid the use of exenatide once weekly and liraglutide in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B.\textsuperscript{10,12,34} The albiglutide prescribing information has a black-box warning in line with those of exenatide once weekly and liraglutide.

To date, there have been no notable cardiovascular adverse events attributed to albiglutide. One recently published, randomized, double-blind, single-center, parallel, nested Phase I cross-over study in healthy adults concluded that albiglutide does not prolong the QTc interval.\textsuperscript{35} The US Food and Drug Administration has requested post-marketing studies on cardiovascular outcomes in patients with a “high baseline risk of cardiovascular disease” and these data remain to be seen.\textsuperscript{4}

Adverse effects

Like other GLP-1 receptor agonists, gastrointestinal adverse effects are those most commonly encountered with use of once-weekly albiglutide. Other common side effects include headache, dizziness, and upper respiratory tract infection. In the largest published albiglutide study to date (albiglutide n=404), the most common side effects associated with albiglutide were diarrhea (14.9%), upper respiratory tract infection (10.4%), nausea (9.9%), injection site reaction (6.9%), urinary tract infection (6.2%), nasopharyngitis (5.9%), headache (5.4%), and vomiting (5.0%).\textsuperscript{25} One subject in the albiglutide group was determined by the pancreatitis adjudication committee to have probable or definite pancreatitis that was at least possibly related to GLP-1 receptor agonist therapy. No cases of thyroid cancer were diagnosed during the trial.\textsuperscript{25} Once-weekly dosing of albiglutide minimizes the side effects seen with larger doses administered at longer intervals. A complete list of adverse effects reported in the published Phase II and III albiglutide clinical trials can be found in Table 3.\textsuperscript{14–17,25}

Drug interactions

The pharmacokinetic effects of albiglutide on warfarin, digoxin, and a low-dose oral contraceptive have been studied.\textsuperscript{37} Although albiglutide was not anticipated to cause cytochrome P450-mediated interactions, the delayed gastric emptying of albiglutide was hypothesized to potentially alter the oral absorption of the concurrently administered agents.\textsuperscript{37} However, the effect of long-acting GLP-1 receptor agonists on gastric emptying decreases rapidly with time, owing to their continuous activation of the GLP-1 receptor, probably due to receptor desensitization.\textsuperscript{38}

Warfarin

Healthy subjects (n=30) were administered a single dose of warfarin 25 mg orally alone (day 1) and after steady-state albiglutide exposure of 50 mg weekly (day 45). Fifteen subjects completed the study and there were no effects on the pharmacokinetic profile of warfarin. Varied doses of albiglutide had no effect on the International Normalized Ratio data.\textsuperscript{37}

Digoxin

Healthy subjects (n=16, all male) were administered a single dose of digoxin 0.5 mg alone (day 1) and again after steady-state albiglutide exposure of 50 mg weekly (day 38). Twenty-four subjects completed the study and there were no effects of albiglutide on the pharmacokinetic profile of digoxin.\textsuperscript{37}
**Table 3** Incidence of adverse events in published clinical trials evaluating once-weekly albiglutide dosing

<table>
<thead>
<tr>
<th>Adverse events n (%)</th>
<th>Albiglutide</th>
<th>Liraglutide</th>
<th>Exenatide</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 mg weekly</td>
<td>9 mg weekly</td>
<td>15 mg weekly</td>
<td>16 mg weekly</td>
</tr>
<tr>
<td>Patients, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (14.3)</td>
<td>1 (7.1)</td>
<td>10 (1.6)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (14.3)</td>
<td>3 (3.2)</td>
<td>8 (8.8)</td>
<td>6 (14.9)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>0</td>
<td>5 (5.8)</td>
<td>0</td>
</tr>
<tr>
<td>Flatulence</td>
<td>0</td>
<td>0</td>
<td>0/8</td>
<td>3/60 (5.0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>0</td>
<td>0</td>
<td>0/8</td>
<td>3/60 (5.0)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0</td>
<td>1 (2.4)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>6 (17.1)</td>
<td>1 (7.1)</td>
<td>5/34 (14.3)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>5 (14.3)</td>
<td>0</td>
<td>2/34 (5.7)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>6 (17.1)</td>
<td>2/34 (5.7)</td>
<td>2/29 (6.5)</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>0</td>
<td>2 (4.8)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>2 (5.7)</td>
<td>20/86 (23.3)</td>
<td>12/83 (14.4)</td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>1 (2.9)</td>
<td>0/34</td>
<td>3/29 (9.7)</td>
<td></td>
</tr>
<tr>
<td>URTI</td>
<td>3 (8.6)</td>
<td>0/34</td>
<td>3/29 (9.7)</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorder</td>
<td>0</td>
<td>0/34</td>
<td>0/29</td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>5 (14.3)</td>
<td>1 (8.3)</td>
<td>1 (8.3)</td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>0</td>
<td>0</td>
<td>2 (15.4)</td>
<td></td>
</tr>
<tr>
<td>Skin reaction*</td>
<td>1 (2.9)</td>
<td>0</td>
<td>9 (10.4)</td>
<td>2 (16.7)</td>
</tr>
<tr>
<td>UTI</td>
<td>0</td>
<td>0/34</td>
<td>25 (6.2)</td>
<td>23 (5.6)</td>
</tr>
<tr>
<td>Positive immunogenicity test</td>
<td>1/35 (2.9)</td>
<td>2/35 (5.7)</td>
<td>2/31 (6.4)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *Includes injection site bruising, erythema, hemorrhage, hypersensitivity, irritation, papule, paresthesia, pruritus, rash, and/or urticaria. Data taken from Seino Y et al, Matthews JE et al, Rosenstock J et al, and Seino Y et al."14–17*

**Abbreviations:** BID, twice daily; NA, not applicable; URTI, upper respiratory tract infection; UTI, urinary tract infection.
Oral contraceptive pill

This study arm was divided into three phases. Phase 1 was a run-in period to ensure all female subjects (n=23) were receiving a 21-day course of oral contraception consisting of norethindrone 0.5 mg and ethinyl estradiol 0.035 mg daily, followed by a 7-day washout period. If subjects were already on an oral contraceptive, they were exempt from the run-in period. During Phase 2 and Phase 3, all patients received 21 days of norethindrone and ethinyl estradiol, followed by 7 days of placebo. Albiglutide 50 mg was administered on day 26 of Phase 2 and on days 5, 12, and 19 of Phase 3. Eighteen subjects completed the study and albiglutide had no effect on the pharmacokinetic profiles of norethindrone and ethinyl estradiol. No clinically meaningful differences were found in concentrations of either luteinizing hormone or follicle-stimulating hormone.37

The study authors concluded from these data that the lack of clinically relevant pharmacokinetic or pharmacodynamic interactions means that no dose adjustments for warfarin, digoxin, or an oral contraceptive containing ethinyl estradiol and norethindrone need to be made when albiglutide is concurrently administered. This is consistent with once-weekly exenatide and liraglutide, which have no meaningful drug-drug interactions of concern.37

Patient preference and adherence

According to the 2012 American Diabetes Association/European Association for the Study of Diabetes position statement, a patient-centered treatment strategy should be guided by an individual patient’s preferences, needs, and values.4 Due to the chronic and progressive nature of type 2 diabetes mellitus, adherence to medication therapy is paramount. The importance of cost, frequency of administration, and tolerance of adverse effects are just a few of the factors that have been demonstrated to impact satisfaction and adherence to treatment in chronic disease states, including hypertension, depression, osteoporosis, and type 2 diabetes mellitus.39–44 For example, several studies have demonstrated that once-weekly dosing is associated with greater adherence than more frequent dosing in patients with osteoporosis.55–47

A survey of 1,516 patients with type 2 diabetes mellitus revealed that once-weekly injectable medications were generally viewed as an attractive option due to perceived convenience.48 Interestingly, weight loss was the characteristic most associated with willingness to take a once-weekly injectable medication.

Patient preference and adherence with use of exenatide once weekly compared with oral regimens and insulin have been nicely reviewed by Doggrell.49 Overall, treatment satisfaction scores were consistently higher with the use of exenatide once weekly when compared with exenatide twice daily, sitagliptin, and pioglitazone.49-50

To date, only one published study has evaluated treatment satisfaction with albiglutide.

The investigators of Harmony 7 assessed treatment satisfaction in 728 patients (of the 812 randomized) in the USA using the Diabetes Medication Satisfaction Questionnaire.51 This questionnaire measures satisfaction in three domains, ie, treatment burden, efficacy, and unwanted side effects. When comparing liraglutide with albiglutide, overall treatment satisfaction scores improved similarly in both groups from baseline.

Currently, there are no published trials evaluating adherence to treatment with albiglutide. However, it is likely that factors influencing adherence to medications for other chronic disease states are applicable to albiglutide.52

Summary

Albiglutide is a novel once-weekly GLP-1 receptor agonist that has demonstrated efficacy by producing favorable reductions in fasting plasma glucose, postprandial plasma glucose, and HbA1C values. Albiglutide is the second once-weekly GLP-1 receptor agonist to be made available for patients with type 2 diabetes mellitus, and may be preferred over other GLP-1 receptor agonists because of its mild side effect profile, convenient once-weekly dosing, and efficacy in patients with renal impairment.

Disclosure

The authors report no conflicts of interest in this work.

References


